New eye drug AVT29 takes on eylea HD in DME trial
NCT ID NCT07489131
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called AVT29 against an approved drug, Eylea HD, for people with diabetic macular edema (DME), a leading cause of vision loss in diabetes. About 256 adults with DME will receive either AVT29 or Eylea HD to see if AVT29 works just as well at improving vision over 8 weeks. The goal is to offer another treatment option for this eye condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Site 3004
RECRUITINGBudapest, Hungary